improving the statistical basis for dose content uniformity.
DR. KIBBE: Do you want to take questions now or do you want to take them after your other two speakers?
DR. ADAMS: I think it might be appropriate, Dr. Kibbe, if we took them later, but it's up to the chair and it's up to Dr. Hussain.
DR. HUSSAIN: I just want to introduce the two individuals to my right. Don Schuirmann and he will participate in the discussion of the committee this morning.
DR. KIBBE: Thank you, Ajaz.
Dr. Olsson, I think we're --
DR. ADAMS: Yes, Dr. Olsson is up next.
DR. KIBBE: Good. Thank you.
DR. OLSSON: Good morning, ladies and gentlemen, and I think I'd like to start out by thanking the FDA for this invitation to give me the opportunity to speak about the parametric tolerance interval test for improved control of delivered-dose uniformity in OINDPs.
I will only, of course, give you an overview